Advertisement
Screener

CRONOS GROUP INC. (CRON) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

2.2 / 5 stars · 30/68 Roast Me

CRONOS GROUP INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

CRONOS GROUP INC. (CRON) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$2.93 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-02-26

  • CRONOS GROUP INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was $43.94M.
  • CRONOS GROUP INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was $7.32M.
  • CRONOS GROUP INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$8.76M.
  • CRONOS GROUP INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was -$2.48M.
  • CRONOS GROUP INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$2.93M, a 107.32% decline from fiscal 2024.
  • CRONOS GROUP INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $40.02M.
  • CRONOS GROUP INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$70.44M.
  • CRONOS GROUP INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$155.18M.
Period endIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed
2025-12-31-$2.93M
10-K · filed 2026-02-26
2024-12-31$43.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$51.27M
derived: sum of 2 quarters · filed 2026-02-26
$42.51M
derived: sum of 3 quarters · filed 2026-02-26
$40.02M
10-K · filed 2026-02-26
2024-09-30$7.32M
10-Q · filed 2024-11-12
-$1.44M
derived: sum of 2 quarters · filed 2024-11-12
-$3.92M
10-Q · filed 2024-11-12
-$49.07M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$8.76M
10-Q · filed 2024-08-08
-$11.24M
10-Q · filed 2024-08-08
-$56.39M
derived: sum of 3 quarters · filed 2026-02-26
-$57.98M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$2.48M
10-Q · filed 2024-05-09
-$47.63M
derived: sum of 2 quarters · filed 2026-02-26
-$49.23M
derived: sum of 3 quarters · filed 2026-02-26
-$54.89M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$45.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$46.74M
derived: sum of 2 quarters · filed 2026-02-26
-$52.40M
derived: sum of 3 quarters · filed 2026-02-26
-$70.44M
10-K · filed 2026-02-26
2023-09-30-$1.59M
10-Q · filed 2024-11-12
-$7.25M
derived: sum of 2 quarters · filed 2024-11-12
-$25.29M
10-Q · filed 2024-11-12
-$101.47M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30-$5.66M
10-Q · filed 2024-08-08
-$23.70M
10-Q · filed 2024-08-08
-$99.88M
derived: sum of 3 quarters · filed 2025-02-27
-$132.98M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31-$18.04M
10-Q · filed 2024-05-09
-$94.22M
derived: sum of 2 quarters · filed 2025-02-27
-$127.32M
derived: sum of 3 quarters · filed 2025-02-27
-$144.85M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31-$76.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$109.29M
derived: sum of 2 quarters · filed 2025-02-27
-$126.81M
derived: sum of 3 quarters · filed 2025-02-27
-$155.18M
10-K · filed 2025-02-27
-$168.73M
10-K · filed 2023-02-28
2022-09-30-$33.10M
10-Q · filed 2023-11-08
-$36.89M
10-Q · filed 2022-11-07
-$50.63M
derived: sum of 2 quarters · filed 2023-11-08
-$79.00M
10-Q · filed 2023-11-08
-$89.88M
10-Q · filed 2022-11-07
$51.45M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30-$17.53M
10-Q · filed 2023-08-08
-$20.34M
10-Q · filed 2022-08-09
-$45.89M
10-Q · filed 2023-08-08
-$52.99M
10-Q · filed 2022-08-09
$84.55M
derived: sum of 3 quarters · filed 2024-02-29
$162.14M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31-$32.65M
10-Q · filed 2022-05-10
$102.08M
derived: sum of 2 quarters · filed 2024-02-29
$179.66M
derived: sum of 3 quarters · filed 2024-02-29
$872.00K
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$134.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$212.32M
derived: sum of 2 quarters · filed 2024-02-29
$33.52M
derived: sum of 3 quarters · filed 2024-02-29
-$128.08M
10-K · filed 2024-02-29
-$396.70M
10-K · filed 2022-03-01
2021-09-30$77.58M
10-Q · filed 2022-11-07
-$101.21M
derived: sum of 2 quarters · filed 2022-11-07
-$262.81M
10-Q · filed 2022-11-07
-$374.39M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$178.79M
10-Q · filed 2022-08-09
$57.34M
10-Q · filed 2021-08-06
-$340.40M
10-Q · filed 2022-08-09
-$104.27M
10-Q · filed 2021-08-06
-$451.98M
derived: sum of 3 quarters · filed 2023-02-28
-$383.04M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$161.60M
10-Q · filed 2022-05-10
-$273.19M
derived: sum of 2 quarters · filed 2023-02-28
-$204.25M
derived: sum of 3 quarters · filed 2023-02-28
-$311.90M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31-$111.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$42.64M
derived: sum of 2 quarters · filed 2023-02-28
-$150.30M
derived: sum of 3 quarters · filed 2023-02-28
-$74.62M
10-K · filed 2023-02-28
2020-09-30$68.94M
10-Q · filed 2022-02-18
-$38.72M
derived: sum of 2 quarters · filed 2022-02-18
$36.96M
10-Q · filed 2022-02-18
$98.83M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$107.66M
10-Q/A · filed 2022-02-18
-$31.98M
10-Q/A · filed 2022-02-18
$29.89M
derived: sum of 3 quarters · filed 2022-03-01
$634.06M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$75.68M
10-Q · filed 2021-05-07
$137.55M
derived: sum of 2 quarters · filed 2022-03-01
$741.72M
derived: sum of 3 quarters · filed 2022-03-01
2019-12-31$61.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$666.03M
derived: sum of 2 quarters · filed 2022-03-01
$1.17B
10-K · filed 2022-03-01
2019-09-30$604.16M
10-Q · filed 2020-11-05
$1.10B
10-Q · filed 2020-11-05
2018-12-31-$20.92M
10-K · filed 2021-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B
Definium Therapeutics, Inc. (DFTX)United States$4.931B-17.87